Literature DB >> 23648935

State-of-the-art medical prevention of postoperative recurrence of Crohn's disease.

Dario Sorrentino1.   

Abstract

Postoperative recurrence of Crohn's disease is a frequent and often severe sequela of the disease. Until a few years ago it was deemed inescapable, as all the conventional medications used to treat the disease have been proven of little benefit in preventing recurrence after surgical treatment. In the past few years, anti-TNF agents given immediately after surgery have shown a remarkable efficacy in the prevention of disease recurrence. Large, randomized, controlled trials are currently underway to confirm these findings. Anti-TNF treatment of endoscopic lesions that occur after surgery seems to be less effective than using TNF antagonists to prevent recurrence. However, although the data are limited, this treatment strategy seems to be still superior to all the other prevention strategies that are not based on anti-TNF agents. Limited data are available on long-term outcomes of patients treated with anti-TNF agents after surgery. They suggest that these medications are safe and effective after many years of treatment. In addition, these agents might prevent recurrence even at doses lower than those used in patients with Crohn's disease who have not had surgery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23648935     DOI: 10.1038/nrgastro.2013.69

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  113 in total

Review 1.  Risk of postoperative recurrence and postoperative management of Crohn's disease.

Authors:  Antonino Spinelli; Matteo Sacchi; Gionata Fiorino; Silvio Danese; Marco Montorsi
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

2.  Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.

Authors:  Konstantinos Papamichael; Emmanuel Archavlis; Constantina Lariou; Gerassimos J Mantzaris
Journal:  J Crohns Colitis       Date:  2012-03-15       Impact factor: 9.071

3.  Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.

Authors:  Casper Steenholdt; Akbar Molazahi; Mark Andrew Ainsworth; Jørn Brynskov; Ole Østergaard Thomsen; Jakob Benedict Seidelin
Journal:  Scand J Gastroenterol       Date:  2012-03-01       Impact factor: 2.423

4.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

5.  Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.

Authors:  R Caprilli; M Cottone; F Tonelli; G Sturniolo; F Castiglione; V Annese; C Papi; A Viscido; C Cammà; G Corrao; G Latella
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 7.  Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.

Authors:  Alexander C Ford; Sunanda V Kane; Khurram J Khan; Jean-Paul Achkar; Nicholas J Talley; John K Marshall; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2011-03-15       Impact factor: 10.864

8.  The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies.

Authors:  George E Reese; Theodore Nanidis; Catherine Borysiewicz; Takayuki Yamamoto; Timothy Orchard; Paris P Tekkis
Journal:  Int J Colorectal Dis       Date:  2008-09-02       Impact factor: 2.571

9.  Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients.

Authors:  Mariam Aguas; Guillermo Bastida; Elena Cerrillo; Belén Beltrán; Marisa Iborra; Cristina Sánchez-Montes; Fernando Muñoz; Jesús Barrio; Sabino Riestra; Pilar Nos
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

10.  Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.

Authors:  Stephen B Hanauer; Burton I Korelitz; Paul Rutgeerts; Mark A Peppercorn; Ronald A Thisted; Russell D Cohen; Daniel H Present
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

View more
  16 in total

1.  Kono-S Anastomosis for Surgical Prophylaxis of Anastomotic Recurrence in Crohn's Disease: an International Multicenter Study.

Authors:  Toru Kono; Alessandro Fichera; Koutarou Maeda; Yoshiharu Sakai; Hiroki Ohge; Mukta Krane; Hidetoshi Katsuno; Mikihiro Fujiya
Journal:  J Gastrointest Surg       Date:  2015-12-22       Impact factor: 3.452

2.  LRRK2 but not ATG16L1 is associated with Paneth cell defect in Japanese Crohn's disease patients.

Authors:  Ta-Chiang Liu; Takeo Naito; Zhenqiu Liu; Kelli L VanDussen; Talin Haritunians; Dalin Li; Katsuya Endo; Yosuke Kawai; Masao Nagasaki; Yoshitaka Kinouchi; Dermot Pb McGovern; Tooru Shimosegawa; Yoichi Kakuta; Thaddeus S Stappenbeck
Journal:  JCI Insight       Date:  2017-03-23

3.  Post-operative recurrence of Crohn's disease after definitive stoma: an underestimated risk.

Authors:  Dine Koriche; Corinne Gower-Rousseau; Charbel Chater; Alain Duhamel; Julia Salleron; Noémie Tavernier; Jean-Frédéric Colombel; Benjamin Pariente; Antoine Cortot; Philippe Zerbib
Journal:  Int J Colorectal Dis       Date:  2016-11-24       Impact factor: 2.571

4.  Long-term prevention of postoperative Crohn's disease recurrence with azathioprine: the wolf in the sheep clothing.

Authors:  Paul M Robb; Dario Sorrentino
Journal:  Int J Colorectal Dis       Date:  2014-08-21       Impact factor: 2.571

Review 5.  Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis.

Authors:  Siddharth Singh; Sushil Kumar Garg; Darrell S Pardi; Zhen Wang; Mohammad Hassan Murad; Edward V Loftus
Journal:  Gastroenterology       Date:  2014-09-26       Impact factor: 22.682

6.  Risk Stratification for Prevention of Recurrence of Postoperative Crohn's Disease.

Authors:  Shirley Cohen-Mekelburg; Yecheskel Schneider; Stephanie Gold; Ellen Scherl; Adam Steinlauf
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-11

7.  Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients.

Authors:  Shirley Cohen-Mekelburg; Stephanie Gold; Yecheskel Schneider; Madison Dennis; Clara Oromendia; Heather Yeo; Fabrizio Michelassi; Ellen Scherl; Adam Steinlauf
Journal:  Dig Dis Sci       Date:  2018-06-07       Impact factor: 3.199

Review 8.  Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults.

Authors:  Gerda C Leitner; Harald Vogelsang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

9.  Perioperative Blood Transfusion and Postoperative Outcome in Patients with Crohn's Disease Undergoing Primary Ileocolonic Resection in the "Biological Era".

Authors:  Yi Li; Luca Stocchi; Yuanyi Rui; Ganglei Liu; Emre Gorgun; Feza H Remzi; Bo Shen
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

Review 10.  Update on the Medical Management of Crohn's Disease.

Authors:  Parakkal Deepak; David H Bruining
Journal:  Curr Gastroenterol Rep       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.